Robert W. Baird Lowers Immutep (NASDAQ:IMMP) Price Target to $6.00

Immutep (NASDAQ:IMMP) had its target price reduced by analysts at Robert W. Baird from $7.00 to $6.00 in a report released on Thursday, Benzinga reports. The brokerage presently has an “outperform” rating on the biotechnology company’s stock. Robert W. Baird’s price target suggests a potential upside of 198.51% from the company’s current price.

Separately, Capital One Financial initiated coverage on shares of Immutep in a research report on Friday, May 17th. They issued an “overweight” rating and a $10.00 target price for the company.

Immutep Stock Up 7.5 %

NASDAQ:IMMP opened at $2.01 on Thursday. The company has a 50-day moving average price of $2.75 and a 200-day moving average price of $2.51. Immutep has a 12 month low of $1.58 and a 12 month high of $3.34.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. BNP Paribas Financial Markets increased its stake in Immutep by 15.4% during the 1st quarter. BNP Paribas Financial Markets now owns 35,300 shares of the biotechnology company’s stock valued at $82,000 after purchasing an additional 4,700 shares in the last quarter. Virtu Financial LLC increased its stake in Immutep by 269.4% during the 1st quarter. Virtu Financial LLC now owns 45,062 shares of the biotechnology company’s stock valued at $105,000 after purchasing an additional 32,864 shares in the last quarter. PFG Investments LLC bought a new stake in Immutep during the 1st quarter valued at about $119,000. Meridian Wealth Management LLC increased its stake in Immutep by 3.6% during the 4th quarter. Meridian Wealth Management LLC now owns 322,450 shares of the biotechnology company’s stock valued at $774,000 after purchasing an additional 11,250 shares in the last quarter. Finally, Oracle Investment Management Inc. increased its stake in Immutep by 9.4% during the 1st quarter. Oracle Investment Management Inc. now owns 564,879 shares of the biotechnology company’s stock valued at $1,316,000 after purchasing an additional 48,449 shares in the last quarter. 2.32% of the stock is owned by hedge funds and other institutional investors.

Immutep Company Profile

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.